Turning Point Brands (TPB) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
15 Jan, 2026Executive summary
Q3 2024 net sales rose 3.8% year-over-year to $105.6 million, with adjusted EBITDA up 11.3% to $27.2 million and net income up 14.3% to $12.4 million, driven by Zig-Zag and Stoker's growth.
Full-year 2024 adjusted EBITDA guidance was raised to $101–$103 million, reflecting confidence in ongoing growth and excluding CDS contributions.
Zig-Zag revenue grew 5.5% to $49.3 million, and Stoker's revenue increased 12.1% to $41.4 million, with both segments showing strong performance.
Free cash flow for Q3 was $12.6 million, supporting capital allocation and shareholder returns.
Growth was supported by internal initiatives, product innovation, and expansion in alternative channels.
Financial highlights
Q3 2024 gross margin improved to 50.8%, with adjusted EBITDA margin at 25.7%.
Operating income for Q3 was $20.5 million, up 1.4% year-over-year.
SG&A expenses were $33.2 million, including higher PMTA and transaction costs.
Cash on hand at quarter-end was $33.6 million, with $58.8 million available under the ABL facility.
Free cash flow generation continues to support business investment and shareholder returns.
Outlook and guidance
2024 adjusted EBITDA guidance raised to $101–$103 million, up from prior $98–$102 million.
CapEx expectation revised down to under $10 million for the year.
Effective income tax rate projected at 23%-26%.
Management expects strong liquidity and free cash flow generation to support operating requirements.
Continued investment in PMTAs for Modern Oral products, with $4 million expected spend for the year.
Latest events from Turning Point Brands
- Modern Oral net sales jumped 266%, driving 29% overall revenue growth and strong 2026 outlook.TPB
Q4 20252 Mar 2026 - Q2 sales and EBITDA rose, guidance increased, and net income jumped 31% on strong segment growth.TPB
Q2 20242 Feb 2026 - FY2024 net sales up 11% and EBITDA up 12%, with strong modern oral and core brand growth.TPB
Q4 202416 Dec 2025 - Board recommends voting for all proposals, emphasizing diversity and governance improvements.TPB
Proxy Filing1 Dec 2025 - Key votes include director elections, auditor change, officer liability limits, and executive pay approval.TPB
Proxy Filing1 Dec 2025 - 2025 annual meeting moved to May 6 and will be held online; proposal deadlines updated.TPB
Proxy Filing1 Dec 2025 - Modern Oral sales soared 651%, driving 25% revenue growth and higher full-year guidance.TPB
Q2 202523 Nov 2025 - Q1 2025 net sales up 28.1%, net income up 19.8%, and Modern Oral sales guidance raised.TPB
Q1 202519 Nov 2025 - Modern Oral sales soared 628% year-over-year, driving record Q3 growth and raised guidance.TPB
Q3 202513 Nov 2025